The COVID-19 pandemic has highlighted the enormous inequities we see in health care outcomes. In the U.S. up to 80% of these disparities can be traced back to the social determinants of health – the conditions in which we all live, work, learn and play. This moderated session will provide you with insights on what one of the prominent pharma companies is doing to advance health equity by advancing solutions and collaborations that help to tackle the social determinants of health, and the importance of how genes affect the diverse populations and their response to medications as shared by a bioengineering professor at Stanford.